Lovega LLC dba Pink Pony Peptides
FDA issued a warning letter to Lovega LLC dba Pink Pony Peptides (Susan Vega, Wellington, FL) after reviewing the company's website in December 2025 and finding that three products — 'GLP-2 TZ' (tirzepatide), 'GLP-3 RT' (retatrutide), and 'Bacteriostatic Water' — were being sold as unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&C Act. Despite 'research purposes only' disclaimers, the website's marketing copy made explicit human-use drug claims including appetite suppression, fat loss, insulin sensitivity, and glucose control. FDA warned that failure to correct violations may result in seizure or injunction, and required a written response within fifteen working days.
Flagged claims (7)
three times the fat-fighting horsepower in one clean, clinical ride
improve metabolic function better than its single-pathway competitors
As a dual GIP and GLP-1 receptor agonist, Tirzepatide helps: o . . . Reduce appetite and increase satiety o . . . Enhance insulin sensitivity and glucose control o . . . Curb cravings without harsh stimulants o . . . Support fat loss over time with clinical precision
As a GIP, GLP-1, and glucagon receptor agonist, Retatrutide offers three times the fat-fighting horsepower in one clean, clinical ride. This cutting-edge peptide has shown jaw-dropping results in clinical trials — helping the body torch fat, suppress appetite, regulate blood sugar, and even improve metabolic function better than its single-pathway competitors.
Originally developed for type 2 diabetes, Tirzepatide has rapidly become a favorite among physicians and wellness experts for its dramatic body recomposition results and long-lasting appetite regulation.
[n]ot for human consumption
laboratory research purposes only
Required actions (3)
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.
Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site audit